Thermo Fisher Scientific acquires Finnzymes

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has completed its previously announced acquisition of Finnzymes. The business is a well-recognized provider of integrated tools for high-performance polymerase chain reaction (PCR), including reagents, instruments, consumables and kits that make the PCR process faster and more accurate for applications including basic genomic research, genetic testing, forensics and food safety.

Finnzymes, which generated full year 2009 revenues of $20 million, will be integrated primarily into Thermo Fisher’s Analytical Technologies Segment, with certain equipment and consumables product lines being added to the Laboratory Products and Services Segment.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Thermo Fisher Scientific Inc.. (2019, June 20). Thermo Fisher Scientific acquires Finnzymes. News-Medical. Retrieved on April 18, 2024 from

  • MLA

    Thermo Fisher Scientific Inc.. "Thermo Fisher Scientific acquires Finnzymes". News-Medical. 18 April 2024. <>.

  • Chicago

    Thermo Fisher Scientific Inc.. "Thermo Fisher Scientific acquires Finnzymes". News-Medical. (accessed April 18, 2024).

  • Harvard

    Thermo Fisher Scientific Inc.. 2019. Thermo Fisher Scientific acquires Finnzymes. News-Medical, viewed 18 April 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New developments at Evosep to make clinical proteomics 100x more robust and 10x faster